StudyFinder
An Early Feasibility Study Assessing Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System (ASPIRE PH)
Recruiting
The objective of this study is to evaluate the safety and feasibility of implantation of the Aria CV PH System in subjects with pulmonary hypertension (PH) and right heart dysfunction. In addition, the study will evaluate early signals of performance of the implanted system.
Male or Female
18 years and over
Inclusion Criteria:
• diagnosis of Right heart dysfunction
• symptomatic despite being on a stable drug regimen
• diagnosis of lung disease, including but not limited to chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD) including idiopathic pulmonary fibrosis (IPF) or combined emphysema with fibrosis
• ineligible for or refuses blood transfusion
• pregnant, nursing or is planning to become pregnant in the next two years
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria
Exclusion Criteria:
• diagnosis of idiopathic hypertrophic subaortic stenosis
• untreated severe aortic or mitral stenosis
• heart failure with reduced ejection fraction
Device: Aria CV Pulmonary Hypertension System
Heart & Vascular
Pulmonary Hypertension, Right Heart Dysfunction
Gretchen Peichel - gpeichel@umn.edu
Thenappan Thenappan
NA
STUDY00011174
See this study on ClinicalTrials.gov